FDA approves oral drug to manage both noise aversion and separation anxiety in dogs 

The U.S Food and Drug Administration (FDA) recently approved the first drug labeled to treat both noise aversion and separation anxiety in dogs. Tessie (tasipimidine oral solution) aims at combating both fear-based behaviors in dogs.  

While both behaviors can be addressed through behavioral modification, the FDA notes that some cases may require medication in addition.  

The active ingredient, tasipimidine, is an alpha-2 adrenoceptor agonist. As such, it targets specific receptors in the brain and  reduces sympathetic nervous system activity helping dogs feel calmer during stressful situations like loud noises or separation from their owner. 

The release from FDA notes that the drug should be administered orally one hour before the start of triggering events and should be given without food due to the potential for delay in the drug’s absorption if taken with food. The release noted that a “small treat” can be given with the medication to help ensure the dog swallows the solution. 

Dogs should be observed for two hours after receiving their first dose, the manufacturer recommended, to monitor for any adverse effects. Drowsiness, uncoordinated movements, or an abnormally slow response when called after receiving treatment may indicate too high a dose. 

In the original New Animal Drug Application (NADA), the FDA notes that dogs can be redosed after three hours, if clinical signs recur for a maximum of three doses within a 24-hour period.  

The drug was sponsored by Orion Corporation, a pharmaceutical company based in Finland. 

Photo credit: © Namscience via iStock/Getty Images Plus

Disclaimer: Trends content is meant to inform, educate, and inspire by providing an array of diverse viewpoints. Any content published should not be viewed as an official stance, position, or endorsement by the American Animal Hospital Association (AAHA) or its Board of Directors.